Skip to main content
Clinical Trials/NCT02736383
NCT02736383CompletedNot Applicable

Effectiveness of Tranexamic Acid (TXA) in Reducing Blood Loss in Hip Fracture Surgery

Spectrum Health Hospitals0 sites142 target enrollmentStarted: May 2016Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
142
Primary Endpoint
Blood Transfusion Rate

Study Overview

Brief Summary

To determine if TXA utilization is effective at reducing transfusion rates in elderly patients undergoing surgery for treatment of a hip fractures.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Retrospective

Eligibility Criteria

Ages
65 Years to — (Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Acute, isolated, unilateral femoral neck, intertrochanteric, and per trochanteric hip fractures confirmed by anteroposterior/lateral hip radiographs, computed tomography, or magnetic resonance imaging.
  • Age 65 and older
  • Low energy mechanism of injury
  • Hip fracture fixation performed within 48 hours
  • English speaking
  • Anticipated medical optimization for operative fixation
  • No other major trauma

Exclusion Criteria

  • Retained hardware around the affected hip
  • Infection around the affected hip
  • Transfer patients with a length of stay > 24 hours at the transferring hospital
  • Diagnosis of deficient natural anticoagulation
  • Known congenital thrombophilia (Deficiency of Protein C, S, Antithrombin)
  • Known allergy to TXA
  • Patients undergoing percutaneous pinning of the hip fracture

Outcomes

Primary Outcomes

Blood Transfusion Rate

Time Frame: 6 weeks

Blood transfusion rates during the patients hospital stay will be assessed.

Secondary Outcomes

  • Hospital Length of stay(6 weeks)
  • Post operative complications(6 weeks)
  • Hospitalization costs(6 weeks)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Similar Trials